Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Lepu Biopharma Co Ltd

2157
Current price
3.2 HKD -0.03 HKD (-0.93%)
Last closed 3.23 HKD
ISIN CNE100004SM4
Sector Healthcare
Industry Biotechnology
Exchange Hong Kong Stock Exchange
Capitalization 5 565 760 591 HKD
Yield for 12 month -16.88 %
1Y
3Y
5Y
10Y
15Y
2157
21.11.2021 - 28.11.2021

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China. Address: No. 651, Lianheng Road, Shanghai, China, 201612

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

38.92 HKD

P/E ratio

Dividend Yield

Current Year

+225 606 464 HKD

Last Year

+15 589 586 HKD

Current Quarter

+153 726 390 HKD

Last Quarter

Current Year

+197 297 536 HKD

Last Year

+13 582 320 HKD

Current Quarter

+147 964 889 HKD

Last Quarter

Key Figures 2157

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -368 218 324 HKD
Operating Margin TTM -137.98 %
PE Ratio
Return On Assets TTM -11.33 %
PEG Ratio
Return On Equity TTM -10.26 %
Wall Street Target Price 38.92 HKD
Revenue TTM 205 313 577 HKD
Book Value 0.54 HKD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -13.2 %
Dividend Yield
Gross Profit TTM 13 582 320 HKD
Earnings per share
Diluted Eps TTM
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin -35.41 %

Dividend Analytics 2157

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 2157

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 2157

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 25.9896
Price Sales TTM 26.8584
Enterprise Value EBITDA 66.5551
Price Book MRQ 5.6107

Financials 2157

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 2157

For 52 weeks

2.16 HKD 6.51 HKD
50 Day MA 3.12 HKD
Shares Short Prior Month
200 Day MA 3.58 HKD
Short Ratio
Shares Short
Short Percent